NPL-2009 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
206Fragile X syndrome1

206. Fragile X syndrome


Clinical trials : 108 Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00637221
(ClinicalTrials.gov)
March 20083/3/2008Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X SyndromeAn Open Label Exploratory Study to Investigate the Safety and Effects of NPL-2009 ( 50 mg - 150 mg Single Dose) on Prepulse Inhibition Tests and Continuous Performance Tasks, in Adults With Fragile X SyndromeFragile X SyndromeDrug: NPL-2009NeuropharmNULLCompleted18 Years45 YearsBoth12Phase 1/Phase 2United States